Our strategy is to develop our portfolio of innovative products for two large market categories, sexual health and pain to late stage, and then partner with major pharmaceutical partners at the optimum time to generate most value.
We are investing in our lead product MED3000 to generate most value for shareholders
The FM57 Phase 3 study was completed and results demonstrated that MED3000 was a clinically proven effective treatment for erectile dysfunction.
Regulatory submissions in EU and US for MED3000 as a medical device.
We are focused on innovative products that are highly differentiated in their markets.
Whilst the primary endpoints of FM57 study were not met compared to placebo, they were met when compared to baseline and showed a positive treatment response for MED3000.
Resources are focused on the submission of required dossiers to regulators in the EU and US.
We aim to improve treatments to give more choice to patients and doctors and improve the quality of life of those suffering from ED and local pain.
We improved the profile of DermaSys® as a platform technology and looked to expand our portfolio.
Improve overall commercial proposition of MED3000 and continue to develop CBD100 with our partner CBDerma Technology.
We are focused on increasing value for shareholders and the quality of life for patients.
The profile of our topical treatment for erectile dysfunction was raised with both the medical community and potential commercial partners.
Increase the profile of MED3000 and value of its unique commercial proposition to potential commercial partners on the back of the data readout from FM57.